Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKUCNSX:BUXNYSE:CRLTSE:EDT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUAkumin$0.18$0.12▼$1.90$26.32M-0.721.38 million shs8.54 million shsBUXBiomark Diagnostics$0.00$0.00▼$0.00N/AN/AN/A11,500 shsCRLCharles River Laboratories International$118.48+1.0%$143.94$91.86▼$254.15$5.82B1.45931,942 shs1.50 million shsEDTSpectral MedicalC$0.81+1.3%C$0.74C$0.43▼C$0.85C$227.81M0.9663,942 shs8,460 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUAkumin0.00%0.00%0.00%0.00%0.00%BUXBiomark Diagnostics0.00%0.00%0.00%0.00%0.00%CRLCharles River Laboratories International+1.90%+9.67%-24.58%-27.42%-49.44%EDTSpectral Medical+2.56%+2.56%+6.67%+53.85%+77.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKUAkuminN/AN/AN/AN/AN/AN/AN/AN/ABUXBiomark DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International4.8273 of 5 stars4.02.00.04.74.03.31.9EDTSpectral MedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKUAkumin 0.00N/AN/AN/ABUXBiomark Diagnostics 0.00N/AN/AN/ACRLCharles River Laboratories International 1.94Reduce$182.0053.61% UpsideEDTSpectral Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BUX, CRL, EDT, and AKU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025CRLCharles River Laboratories InternationalBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$160.00 ➝ $145.004/9/2025CRLCharles River Laboratories InternationalMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$175.00 ➝ $155.003/21/2025CRLCharles River Laboratories InternationalThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$190.00 ➝ $170.003/4/2025CRLCharles River Laboratories InternationalCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell ➝ Neutral$155.00 ➝ $175.003/3/2025CRLCharles River Laboratories InternationalRedburn AtlanticSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell ➝ Neutral$188.002/20/2025CRLCharles River Laboratories InternationalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$175.00 ➝ $165.002/20/2025CRLCharles River Laboratories InternationalRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$177.00 ➝ $173.002/18/2025CRLCharles River Laboratories InternationalBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$205.00 ➝ $166.002/5/2025CRLCharles River Laboratories InternationalMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$220.00 ➝ $184.002/3/2025CRLCharles River Laboratories InternationalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$215.00 ➝ $175.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKUAkumin$749.63M0.00N/AN/A$1.24 per share0.00BUXBiomark DiagnosticsN/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International$4.05B1.44$15.84 per share7.48$67.80 per share1.75EDTSpectral MedicalC$1.90M119.90C$0.01 per share82.50C($0.08) per share-10.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKUAkumin-$156.76M-$2.52N/AN/AN/A-30.56%-167.86%-7.81%N/ABUXBiomark DiagnosticsN/AN/A0.00N/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International$474.62M$0.15789.8710.774.540.52%14.69%6.79%5/7/2025 (Estimated)EDTSpectral Medical-C$18.68M-C$0.07N/A∞N/AN/A-973.97%-93.22%N/ALatest BUX, CRL, EDT, and AKU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025CRLCharles River Laboratories International$2.06N/AN/AN/A$942.34 millionN/A2/19/2025Q4 2024CRLCharles River Laboratories International$2.50$2.66+$0.16-$4.22$983.63 million$1.00 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKUAkuminN/AN/AN/AN/AN/ABUXBiomark DiagnosticsN/AN/AN/AN/AN/ACRLCharles River Laboratories InternationalN/AN/AN/AN/AN/AEDTSpectral MedicalN/A1.45%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKUAkumin17.020.990.99BUXBiomark DiagnosticsN/AN/AN/ACRLCharles River Laboratories International0.651.411.14EDTSpectral Medical26.030.610.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKUAkumin36.10%BUXBiomark DiagnosticsN/ACRLCharles River Laboratories International98.91%EDTSpectral Medical12.99%Insider OwnershipCompanyInsider OwnershipAKUAkumin20.51%BUXBiomark DiagnosticsN/ACRLCharles River Laboratories International1.30%EDTSpectral Medical18.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKUAkumin3,63191.17 million72.47 millionNot OptionableBUXBiomark DiagnosticsN/AN/AN/ANot OptionableCRLCharles River Laboratories International21,40049.12 million50.47 millionOptionableEDTSpectral Medical29281.25 millionN/ANot OptionableBUX, CRL, EDT, and AKU HeadlinesRecent News About These CompaniesSpectral Medical (TSE:EDT) Stock Price Crosses Above 50 Day Moving Average - Should You Sell?April 26, 2025 | marketbeat.comSpectral Medical (TSE:EDT) Sets New 1-Year High - Should You Buy?April 18, 2025 | marketbeat.comSpectral Medical (TSE:EDT) Stock Price Passes Above 50-Day Moving Average - Here's WhyApril 11, 2025 | marketbeat.comSpectral Medical (TSE:EDT) Share Price Passes Above 50-Day Moving Average - Time to Sell?April 2, 2025 | marketbeat.comSpectral Medical Full Year 2024 Earnings: Beats ExpectationsMarch 29, 2025 | finance.yahoo.comStocks in play: Spectral Medical Inc.March 27, 2025 | ca.finance.yahoo.comSpectral Medical Advances Amid Tigris Trial ChallengesDecember 3, 2024 | markets.businessinsider.comThe top TSX healthcare stocks under $1November 5, 2024 | msn.comSpectral Medical Nears Completion of Tigris TrialNovember 4, 2024 | markets.businessinsider.comSpectral announces last patient out in U.S. burn pivotal study at Burns CenterOctober 30, 2024 | markets.businessinsider.comSpectral AI Names Company Founder As Its New Board ChairmanOctober 19, 2024 | dallasinnovates.comSpectral Medical Provides September Tigris Trial UpdateOctober 3, 2024 | finance.yahoo.com12 Horrifyingly Haunted Hotels You Can Actually Stay at—If You DareSeptember 29, 2024 | currently.att.yahoo.comHow To Avoid Being Duped By Medical DisinformationSeptember 25, 2024 | forbes.comOPINION: We don't need a new prison in Letcher County, Kentucky, or anywhere elseSeptember 24, 2024 | news.yahoo.com'The Substance' review: Demi Moore dazzles in a derivative midnight snoozeSeptember 20, 2024 | yahoo.comSpectral AI Outlines U.S. Regulatory Pathway for DeepView® System for Burn IndicationSeptember 17, 2024 | tmcnet.comPaul M. Walker Sells 150,000 Shares of Spectral Medical Inc. (TSE:EDT) StockSeptember 17, 2024 | insidertrades.comInside HHS’ AI purchasesSeptember 15, 2024 | politico.comSpectral Medical Inc EDTAugust 17, 2024 | morningstar.comFDA rejection of MDMA-assisted therapy rattles advocates but doesn’t spell end of psychedelics in medicine, experts sayAugust 14, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Medtronic: A Dividend Aristocrat With Stability and InnovationBy Jeffrey Neal Johnson | April 22, 2025View Medtronic: A Dividend Aristocrat With Stability and InnovationThe 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?By Ryan Hasson | April 16, 2025View The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? By Chris Markoch | April 16, 2025View Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Duolingo Stock: EdTech Growth Meets Subscription StrengthBy Jeffrey Neal Johnson | April 21, 2025View Duolingo Stock: EdTech Growth Meets Subscription StrengthBUX, CRL, EDT, and AKU Company DescriptionsAkumin NASDAQ:AKUAkumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other diagnostic and interventional radiology procedures through owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to hospitals and health systems across 48 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.Biomark Diagnostics CNSX:BUXBioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.Charles River Laboratories International NYSE:CRL$118.48 +1.19 (+1.01%) As of 03:59 PM EasternCharles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.Spectral Medical TSE:EDTC$0.81 +0.01 (+1.25%) As of 03:59 PM EasternSpectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. The segments of the group are Spectral Medical Inc, which is the key revenue-generating segment that manufactures and sells its EAA diagnostic and certain proprietary reagents; Dialco Medical Inc segment; and Corporate. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
